The global market for mRNA therapeutics was valued at $7.71 billion in 2025 and is forecast to remain stable or slightly decline to $7.69 billion by the end of 2030, at a compound annual growth rate (CAGR) of -0.04% during the forecast period of 2025 to 2030.
Therapies using messenger ribonucleic acid, or mRNA, have immense potential for treating chronic diseases. Vaccines incorporating mRNA provide several advantages over DNA vaccines in manufacturing, distribution and safety. There is a demand for vaccines and treatments using mRNA because of their encouraging results in human clinical trials. The market is expanding due to increased clinical trials and the global proliferation of stem cell therapies. Governments, academic institutions and biotech and pharma companies are concentrating on detecting infectious and rare diseases. The global market for mRNA therapeutics market presents a multibillion-dollar opportunity for vaccines and other therapies.
COVID-19 mRNA-based vaccines are currently available, and research continues to find new methods for preventing and treating infections and illnesses. Essential for many bodily functions, mRNA instructs the body’s cells to produce proteins. Essentially, mRNA participates in biological processes within our bodies to potentially treat diseases and stop infections.
Therapies using messenger ribonucleic acid, or mRNA, have immense potential for treating chronic diseases. Vaccines incorporating mRNA provide several advantages over DNA vaccines in manufacturing, distribution and safety. There is a demand for vaccines and treatments using mRNA because of their encouraging results in human clinical trials. The market is expanding due to increased clinical trials and the global proliferation of stem cell therapies. Governments, academic institutions and biotech and pharma companies are concentrating on detecting infectious and rare diseases. The global market for mRNA therapeutics market presents a multibillion-dollar opportunity for vaccines and other therapies.
COVID-19 mRNA-based vaccines are currently available, and research continues to find new methods for preventing and treating infections and illnesses. Essential for many bodily functions, mRNA instructs the body’s cells to produce proteins. Essentially, mRNA participates in biological processes within our bodies to potentially treat diseases and stop infections.
Report Scope
The report analyzes the global market for mRNA therapeutics. It includes global revenue ($ millions) for the base year of 2024, estimated data for 2025 and projected compound annual growth rates (CAGRs) through 2030. The report examines the different types of mRNA and their applications for therapeutic use. It also focuses on mRNA patents and clinical trials and examines the trends affecting the market during the forecast period. The report profiles the leading companies and their strategic alliances and partnerships. The report segments the global market into North America, Europe, Asia-Pacific (APAC) and the Rest of the World (RoW).Report Includes
- 19 data tables and 71 additional tables
- An overview and analysis of the global markets for messenger RNA (mRNA)-based therapeutics
- Analyses of the global market trends, with revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
- Estimates of the size and revenue prospects for the global mRNA market, along with a market share analysis by disease type, indication, and region
- Facts and figures pertaining to market dynamics, opportunities and deterrents, technological advances, regulations and the impacts of macroeconomic variables
- Insights derived from Porter’s Five Forces model, global supply chain and PESTLE analyses
- Patent analysis, featuring key granted and published patents
- Overview of the sustainability trends and ESG developments in the industry, with emphasis on the ESG practices followed by leading companies, their ESG ratings and consumer attitudes
- Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
- Profiles of the leading companies, including Moderna Inc., Pfizer Inc., BioNTech SE, Merck & Co., and Sanofi
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Pipeline and Clinical Trial Analysis
Chapter 6 Market Segmentation Analysis
Chapter 7 Emerging Technologies and Developments
Chapter 8 Patent Analysis
Chapter 9 Sustainability in the mRNA Therapeutics Industry: An ESG Perspective
Chapter 10 Competitive Intelligence
Chapter 11 Appendix
List of Tables
List of Figures
Companies Mentioned
- Arcturus Therapeutics Inc.
- Astrazeneca
- Biocina
- Biontech Se
- Curevac Se
- Ethris Gmbh
- Gennova Biopharmaceuticals Ltd.
- GSK Plc.
- Immorna (Hangzhou) Biotechnology Co. Ltd.
- Merck & Co. Inc.
- Moderna Inc.
- Nutcracker Therapeutics Inc.
- Pfizer Inc.
- Providence Therapeutics
- Sanofi
- Strand Therapeutics Inc.
